Improving Global Outcomes (KDIGO) guidelines recommends monitoring chronic kidney disease mineral and bone disorder biochemical markers, including PTH, calcium, phosphorus, and ALP, in patients with moderate-to-severe chronic kidney disease [43]. The gene discussed is PTH; the disease is bone disorder.